Tigecycline: Difference between revisions
m Protected "Tigecycline": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| Line 21: | Line 21: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Tigecycline''' ([[International Nonproprietary Name|INN]]) ([[International Phonetic Alphabet|IPA]]: {{IPA|[ ˌtaɪgəˈsaɪklin ]}}) is an [[glycylcycline]] [[antibiotic]] developed and marketed by [[Wyeth]] under the brand name '''Tygacil'''. It was given a U.S. [[Food and Drug Administration]] (FDA) fast-track approval and was approved on [[June 17]], [[2005]]. It was developed in response to the growing prevalence of [[antibiotic resistance]] in bacteria such as ''[[Staphylococcus aureus]]''. | '''Tigecycline''' ([[International Nonproprietary Name|INN]]) ([[International Phonetic Alphabet|IPA]]: {{IPA|[ ˌtaɪgəˈsaɪklin ]}}) is an [[glycylcycline]] [[antibiotic]] developed and marketed by [[Wyeth]] under the brand name '''Tygacil'''. It was given a U.S. [[Food and Drug Administration]] (FDA) fast-track approval and was approved on [[June 17]], [[2005]]. It was developed in response to the growing prevalence of [[antibiotic resistance]] in bacteria such as ''[[Staphylococcus aureus]]''. | ||
| Line 46: | Line 46: | ||
{{TetracyclineAntiBiotics}} | {{TetracyclineAntiBiotics}} | ||
[[Category:Glycylcycline antibiotics]] | [[Category:Glycylcycline antibiotics]] | ||
[[de:Tigecyclin]] | [[de:Tigecyclin]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 16:56, 20 August 2012
| File:Tigecycline structure.svg | |
| Clinical data | |
|---|---|
| Pregnancy category | |
| Routes of administration | IV only |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | NA |
| Protein binding | 71-89% |
| Metabolism | not metabolised |
| Elimination half-life | 42.4 hours |
| Excretion | 59% biliary, 33% renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C19H39N5O8 |
| Molar mass | 585.65 g/mol |
|
WikiDoc Resources for Tigecycline |
|
Articles |
|---|
|
Most recent articles on Tigecycline Most cited articles on Tigecycline |
|
Media |
|
Powerpoint slides on Tigecycline |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Tigecycline at Clinical Trials.gov Clinical Trials on Tigecycline at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Tigecycline
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Tigecycline Discussion groups on Tigecycline Patient Handouts on Tigecycline Directions to Hospitals Treating Tigecycline Risk calculators and risk factors for Tigecycline
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Tigecycline |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Tigecycline (INN) (IPA: Template:IPA) is an glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was given a U.S. Food and Drug Administration (FDA) fast-track approval and was approved on June 17, 2005. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus.
Pharmacology
This antibiotic is the first clinically-available drug in a new class of antibiotics called the glycylcyclines. It is structurally similar to the tetracyclines in that it contains a central four-ring carbocyclic skeleton and is actually a derivative of minocycline. Tigecycline has a substitution at the D-9 position which is believed to confer broad spectrum activity. The drug inhibits the bacterial 30S ribosome and is bacteriostatic.
Indications
Tigecycline is active against many Gram-positive bacteria, Gram-negative bacteria and anaerobes – including activity against methicillin-resistant Staphylococcus aureus (MRSA). It has no activity against Pseudomonas spp. or Proteus spp. The drug is licenced for the treatment of skin and soft tissue infections as well as intra-abdominal infections.
Dosing
Tigecycline is given by slow intravenous infusion (30 to 60 minutes). A single dose of 100 mg is given first, followed by 50 mg every twelve hours after that. Patients with impaired liver function need to be given a lower dose. No adjustment is needed for patients with impaired kidney function. It is not licensed for use in children. There is no oral form available.
Side Effects
The most common side effects of tigecycline are diarrhea, nausea and vomiting. Nausea and vomiting is mild or moderate and usually occurs during the first two days of therapy. Other side effects include pain at the injection site, swelling and irritation; increased or decreased heart rate and infections. As tigecycline is similar to the tetracycline antibiotics,they have similar side effects such as increased sensitivity to sunlight. Also avoid use in children and pregnancy, due to its affects on teeth and bone. As with other antibiotics, overgrowth of organisms that are not susceptible to tigecycline can occur.
References
- Rose W, Rybak M (2006). "Tigecycline: first of a new class of antimicrobial agents". Pharmacotherapy. 26 (8): 1099–110. PMID 16863487.
- Kasbekar N (2006). "Tigecycline: a new glycylcycline antimicrobial agent". Am J Health Syst Pharm. 63 (13): 1235–43. PMID 16790575.
External links
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Glycylcycline antibiotics